Vystar posted a net loss of USD 225,485 in the quarter ended June 30, 2026, narrowing 47.2%.
Revenue fell 33.1% to USD 7,767 on reduced channel sales.
Operating loss narrowed 37.6% to USD 166,887 as operating expenses dropped 36.4% to USD 174,175.
Interest expense decreased 15.2% to USD 134,867; results included a USD 76,725 gain on settlement of debt.
Product development update
Prototype RxAir testing integrating Fluid Energy conversion technology with the Hughes Reactor is expected to finish by end-2026, with production targeted late 2027.
VYST•
